Presentation is loading. Please wait.

Presentation is loading. Please wait.

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with.

Published byLinn Kleppe Modified over 5 years ago

Similar presentations

Presentation on theme: "Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with."— Presentation transcript:

1 Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial  Andrew Blauvelt, MD, MBA, Kim A. Papp, MD, PhD, Christopher E.M. Griffiths, MD, Bruce Randazzo, MD, PhD, Yasmine Wasfi, MD, PhD, Yaung-Kaung Shen, PhD, Shu Li, PhD, Alexa B. Kimball, MPH, MD  Journal of the American Academy of Dermatology  Volume 76, Issue 3, Pages (March 2017) DOI: /j.jaad Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

2 Fig 1 Psoriasis. Study schema.
Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

3 Fig 2 Psoriasis. Consolidated Standards of Reporting Trials diagram.
Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

4 Fig 3 Psoriasis. Clinical efficacy through week 48. Proportion of patients achieving (A) IGA 0/1, (B) IGA 0, (C) PASI 75, (D) PASI 90, and (E) PASI 100 responses. IGA 0/1, Investigator Global Assessment score of cleared (0) or minimal (1); IGA 0, Investigator Global Assessment score of 0 (cleared); PASI 75, 75% or greater improvement in Psoriasis Area and Severity Index score from baseline; PASI 90, 90% or greater improvement in Psoriasis Area and Severity Index score from baseline; PASI 100, 100% improvement in Psoriasis Area and Severity Index score from baseline. Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

5 Fig 4 Psoriasis. Distribution of PASI responses at week 48. PASI, Psoriasis Area and Severity Index; PASI 50, 50% or greater improvement in Psoriasis Area and Severity Index score from baseline; PASI 75, 75% or greater improvement in Psoriasis Area and Severity Index score from baseline; PASI 90, 90% or greater improvement in Psoriasis Area and Severity Index score from baseline; PASI 100, 100% improvement in Psoriasis Area and Severity Index score from baseline. Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

Download ppt "Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with."

Similar presentations

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study  Jerry.

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study  Jerry.
Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.

Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial  Diamant.

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial  Diamant.
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to- severe plaque psoriasis up to 1 year: Results from the CLEAR study 

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to- severe plaque psoriasis up to 1 year: Results from the CLEAR study 
A girl with a solitary red bulla

A girl with a solitary red bulla
Efficacy of the long-pulsed 1064-nm neodymium:yttrium-aluminum-garnet laser (LPND) (rejuvenation mode) in the treatment of papulopustular rosacea (PPR):

Efficacy of the long-pulsed 1064-nm neodymium:yttrium-aluminum-garnet laser (LPND) (rejuvenation mode) in the treatment of papulopustular rosacea (PPR):
Yul W. Yang, MD, PhD, David J. DiCaudo, MD 

Yul W. Yang, MD, PhD, David J. DiCaudo, MD 
OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results  Alexa B. Kimball,

OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results  Alexa B. Kimball,
Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional.

Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional.
Efficacy of simvastatin in plaque psoriasis: A pilot study

Efficacy of simvastatin in plaque psoriasis: A pilot study
Sarah Sung, MD, Alexa B. Kimball, MD, MPH 

Sarah Sung, MD, Alexa B. Kimball, MD, MPH 
Deficiency of serum concentration of 25-hydroxyvitamin D correlates with severity of disease in chronic plaque psoriasis  Federica Ricceri, MD, Leonardo.

Deficiency of serum concentration of 25-hydroxyvitamin D correlates with severity of disease in chronic plaque psoriasis  Federica Ricceri, MD, Leonardo.
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.
OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild.

OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild.
Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from.

Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from.
The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study  Hsien-Yi Chiu, MD, Tsen-Fang.

The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study  Hsien-Yi Chiu, MD, Tsen-Fang.
A double-blind, placebo-controlled, phase-II clinical trial to evaluate oral simvastatin as a treatment for vitiligo  Stefan G. Vanderweil, MD, Shinya.

A double-blind, placebo-controlled, phase-II clinical trial to evaluate oral simvastatin as a treatment for vitiligo  Stefan G. Vanderweil, MD, Shinya.
Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial  Catherine Maari, MD, FRCPC, Philippe Marchessault,

Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial  Catherine Maari, MD, FRCPC, Philippe Marchessault,
A randomized, double-blind, vehicle-controlled, bilateral comparison trial of bexarotene gel 1% versus vehicle gel in combination with narrowband UVB.

A randomized, double-blind, vehicle-controlled, bilateral comparison trial of bexarotene gel 1% versus vehicle gel in combination with narrowband UVB.
Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled.

Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled.

Similar presentations

Ads by Google